Functional Consequences of a SDHB Gene Mutation in an Apparently Sporadic Pheochromocytoma
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Three genes encoding for mitochondrial complex II proteins are linked to hereditary paraganglioma. We have recently shown that an inactivation of the SDHD gene is associated with a complete loss of mitochondrial complex II activity and a stimulation of the angiogenic pathway (Gimenez-Roqueplo, A. P., J. Favier, P. Rustin, J. J. Mourad, P. F. Plouin, P. Corvol, A. Rötig, and X. Jeunemaitre, 2001, Am J Hum Genet 69:1186-1197). Here, we relate the case of a malignant sporadic pheochromocytoma induced by a germline missense mutation of the SDHB gene. Within the tumor, a loss of heterozygosity at chromosome 1pter led to a null SDHB allele and to a complete loss of complex II enzymatic activity. In situ hybridization and immunohistochemistry experiments showed a high expression of hypoxic-angiogenic responsive genes, similar to that previously observed in inherited-SDHD tumors. This observation highlights the role of the complex II mitochondrial genes in the oxygen-sensing pathway and in the regulation of angiogenesis of neural crest-derived tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mitochondrial complex II is a component of the electron transport chain, and mutations of SDHB or SDHD genes that abrogate the oxidoreductase function of complex II can cause pheochromocytomas [9,14,15].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [14]
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“The SDHD and SDHC genes were sequenced as previously described (1, 3).”
MethodGerm-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Cellular oxygen sensing by mitochondria: old questions, new insight
Chandel, N. S., & Schumacker, P. T. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.5.1880 · Cited by 391
Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Mourad, J.-J., Plouin, P.-F., Corvol, P., Rötig, A., & Jeunemaitre, X. (2001) · The American Journal of Human Genetics · doi:10.1086/324413 · Cited by 364 · cited 6×
“The expression of five genes (EPAS1, VEGF, VEGFR-1, VEGFR-2, and neuron-specific enolase) encoding angiogenic and hypoxia-induced factors was studied in SDHB-mutated pheochromocytoma tissue by immunohistochemistry and in situ hybridization with procedures previously described (5, 9).”
BackgroundMethodSelf-citationSuccinate dehydrogenase and fumarate reductase from Escherichia coli
Cecchini, G., Schröder, I., Gunsalus, R. P., & Maklashina, E. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(01)00238-9 · Cited by 283 · cited 4×
“00/0 The Journal of Clinical Endocrinology & Metabolism 87(10):4771–4774”
BackgroundInfluentialGimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Germline SDHD mutation in familial phaeochromocytoma
Astuti, D., Douglas, F., Lennard, T. W., Aligianis, I. A., Woodward, E. R., Evans, D. G. R., Eng, C., Latif, F., & Maher, E. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04378-6 · Cited by 246 · cited 1×
“catecholamine-secreting pheochromocytomas (5, 6), heredi-”
Enhancement of mRNA in situ hybridization signal by microwave heating.
Sibony, M., Commo, F., Callard, P., & Gasc, J. (1995) · PubMed · Cited by 135
Cited by
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
“A single phaeochromocytoma from a patient with an R46Q SDHB mutation showed high expression of EPAS1 and VEGF mRNAs, but HIF1a was not studied (25).”
BackgroundSelf-citationGenetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Self-citationSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672
“This is supported by the observation that mutations in either SDHB or SDHD result in the disintegration of the SDH complex and a complete loss of SDH enzymatic activity (Gimenez-Roqueplo et al., 2001; Gimenez-Roqueplo et al., 2002; Douwes Dekker et al., 2003).”
BackgroundJaneway, K. A., Kim, S. Y., Lodish, M., Nosé, V., Rustin, P., Gaal, J., Dahia, P. L. M., Liegl, B., Ball, E. R., Raygada, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009199108 · Cited by 628
Self-citationMitochondrial tumour suppressors: a genetic and biochemical update
Gottlieb, E., & Tomlinson, I. P. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1737 · Cited by 621
Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes
Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1862 · Cited by 570
“d Previously published case (13). e Previously published case ( 10 ).”
BackgroundSelf-citationMutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaître, X. (2003) · PubMed · Cited by 609
Self-citationvan Nederveen, F. H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. A., de Bruyn, E. M., Sleddens, H. F., Derkx, P., Rivière, J., Dannenberg, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70164-0 · Cited by 538
Self-citationZeviani, M., & Spinazzola, A. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0026-9 · Cited by 533
Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0709 · Cited by 450
“They include eight different missense mutations in 13 patients (14, 15, 17, 24, 25), one nonsense (26) and one splicing mutation (27) in one patient each, and three different frame-shift mutations in five patients (15, 16).”
BackgroundSelf-citationA HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
“Mitochondrial complex II is a component of the electron transport chain, and mutations of SDHB or SDHD genes that abrogate the oxidoreductase function of complex II can cause pheochromocytomas [9,14,15].”
Oncometabolites: linking altered metabolism with cancer
Yang, M., Soga, T., & Pollard, P. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67228 · Cited by 422
“6, 30–32, and Figure 2).”
Bardella, C., Pollard, P. J., & Tomlinson, I. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.07.003 · Cited by 395
A role for mitochondrial enzymes in inherited neoplasia and beyond
Eng, C., Kiuru, M., Fernandez, M. J., & Aaltonen, L. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1013 · Cited by 392
“Virtually all tumours that are associated with both syndromes have been shown to have lost the remaining wild-type allel”
BackgroundBurnichon, N., Rohmer, V., Amar, L., Herman, P., Leboulleux, S., Darrouzet, V., Niccoli, P., Gaillard, D., Chabrier, G., Chabolle, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2504 · Cited by 378
“When frozen tumor tissues were available, we: 1) searched for exon skipping in cDNA for unknown variants located in splice sites (after extraction of tumor RNA and RTPCR); 2) tested for loss of heterozygosity at the SDH locus using tumoral and peripheral DNA and microsatellite markers as described elsewhere (14, 15);…”
MethodSelf-citationMacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01927-06 · Cited by 359
“Pseudohypoxia was also shown recently in tumor cells with mutations in fumarate hydratase (FH) or in any of three of the four subunits of succinate dehydrogenase (SDH), SDHB, SDHC, or SDHD (5, 8, 9, 19, 20, 28).”
BackgroundInfluentialTimmers, H. J. L. M., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Havekes, B., Eisenhofer, G., Martiniova, L., Adams, K. T., & Pacak, K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1248 · Cited by 348
“SDHB mutations can lead to complete loss of succinate dehydrogenase enzymatic activity in malignant PGL, with up-regulation of hypoxic-angiogenetic responsive genes (39).”
BackgroundGermline SDHB Mutations and Familial Renal Cell Carcinoma
Ricketts, C., Woodward, E. R., Killick, P., Morris, M. R., Astuti, D., Latif, F., & Maher, E. R. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn254 · Cited by 342
Chen, J.-Q., & Russo, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.004 · Cited by 327
Timmers, H. J. L. M., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Eisenhofer, G., King, K. S., Rao, J. U., Wesley, R. A., Adams, K. T., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs188 · Cited by 283
Gill, A. J., Benn, D. E., Chou, A., Clarkson, A., Muljono, A., Meyer-Rochow, G. Y., Richardson, A. L., Sidhu, S. B., Robinson, B. G., & Clifton-Bligh, R. J. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.12.005 · Cited by 277
Pasini, B., & Stratakis, C. A. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02111.x · Cited by 273
“The same group [79] studied the biological effect of a missense SDHB germline mutation (p.Arg46Gln) in a malignant PHEO with somatic terminal deletion of 1p.”
Lussey-Lepoutre, C., Hollinshead, K. E. R., Ludwig, C., Menara, M., Morin, A., Castro-Vega, L.-J., Parker, S. J., Janin, M., Martinelli, C., Ottolenghi, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9784 · Cited by 227
“Consistent with the pseudohypoxic phenotype previously reported in SDH-deficient cells 9,14 , we noted increased lactate production and excretion (Fig.”
Self-citationRegulation of succinate dehydrogenase and role of succinate in cancer
Dalla Pozza, E., Dando, I., Pacchiana, R., Liboi, E., Scupoli, M. T., Donadelli, M., & Palmieri, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.04.013 · Cited by 212
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background
Fishbein, L., & Nathanson, K. L. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.01.009 · Cited by 208
“SDHB acts as a tumor suppressor gene, with LOH seen in the tumors as the second hit (68, 69).”
BackgroundPheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment
Martucci, V. L., & Pacak, K. (2014) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2014.01.001 · Cited by 204
Bayley, J.-P., Devilee, P., & Taschner, P. E. (2005) · BMC Medical Genetics · doi:10.1186/1471-2350-6-39 · Cited by 184
“More curious, however is the small number of SDHC mutations reported, despite inclusion of SDHC in many of the screening efforts of paraganglioma/pheochromocytoma patients [15-22].”
BackgroundCurrent and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Jimenez, C., Rohren, E., Habra, M. A., Rich, T., Jimenez, P., Ayala-Ramirez, M., & Baudin, E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0320-x · Cited by 178
“Metastatic disease and decreased overall survival duration are observed in approximately 50 % of patients with a PH or SPG associated with SDHB mutations [32, 33].”
BackgroundPollard, P. J., Spencer-Dene, B., Shukla, D., Howarth, K., Nye, E., El-Bahrawy, M., Deheragoda, M., Joannou, M., McDonald, S., Martin, A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.005 · Cited by 178
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
“(136,140) described overexpression of HIF-2α and VEGF in patients with PHEOs and PGLs carrying SDHB and SDHD mutations compared with sporadic PHEOs and PGLs.”
BackgroundBayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
“HIF1α targets, including vascular endothelial growth factor (VEGF), erythropoietin (EPO), and glucose transporter1 (GLUT1), show activation on accumulation of TCA metabolites, and contribute to an increase in microvessel density [18,20,22-26].”
BackgroundOncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
“We further demonstrated that the abundance of both hypoxia-inducible factor-2a (HIF-2a) and vascular endothelial growth factor (VEGF) was higher in tumors from SDHx mutation carriers than in tumors from patients without these mutations.(22,23) HIF-1 and HIF-2 are the main transcription factors involved in cellular and…”
BackgroundSelf-citationAyala‐Ramirez, M., Feng, L., Habra, M. A., Rich, T., Dickson, P. V., Perrier, N., Phan, A., Waguespack, S., Patel, S., & Jimenez, C. (2012) · Cancer · doi:10.1002/cncr.26577 · Cited by 161
“Median age [range], y 44 [33-50] 42 [13-70] 42 [13-70] .”
The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
Pollard, P., Wortham, N., & Tomlinson, I. (2003) · Annals of Medicine · doi:10.1080/07853890310018458 · Cited by 159
Phaeochromocytoma, new genes and screening strategies
Gimenez‐Roqueplo, A., Lehnert, H., Mannelli, M., Neumann, H., Opocher, G., Maher, E. R., Plouin, P., & on behalf of the European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02714.x · Cited by 145
Self-citationClinical aspects of SDHx-related pheochromocytoma and paraganglioma
Timmers, H. J. L. M., Gimenez-Roqueplo, A.-P., Mannelli, M., & Pacak, K. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0284 · Cited by 131
“In SDHB and SDHD-associated PGL, this was shown to result in a complete abolition of SDH enzymatic activity and an activation of the hypoxic‐angiogenic pathway via an activation of the transcription hypoxia-inducible factor (HIF1-a) and its main target genes such as VEGF ( Gimenez-Roqueplo et al. 2001, 2002 ).”
Self-citationFITZGERALD, P. A., Goldsby, R. E., Huberty, J. P., Price, D. C., Hawkins, R. A., Veatch, J., Cruz, F. S. D., Jahan, T. M., LINKER, C. A., Damon, L. E., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.050 · Cited by 127
Taïeb, D., Nölting, S., Perrier, N. D., Faßnacht, M., Carrasquillo, J. A., Grossman, A. B., Clifton-Bligh, R. J., Wanna, G. B., Schwam, Z. G., Amar, L., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00926-0 · Cited by 128
Self-citationNew imaging approaches to phaeochromocytomas and paragangliomas
Havekes, B., King, K. S., Lai, E. W., Romijn, J. A., Corssmit, E. P. M., & Pacák, K. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03648.x · Cited by 123
Tseng, P., Wu, W.-H., Hu, T., Chen, C., Cheng, H.-C., Li, C., Tsai, W., Tsai, H.-J., Hsieh, M.-C., Chuang, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21361-6 · Cited by 129
Cancer-derived extracellular succinate: a driver of cancer metastasis
Kuo, C.-C., Wu, J.-Y., & Wu, K. K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00878-z · Cited by 125
Pheochromocytomas: The (pseudo)-hypoxia hypothesis
Favier, J., & Gimenez‐Roqueplo, A. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.10.004 · Cited by 124
Self-citationPillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 126
Fliedner, S. M. J., Lehnert, H., & Pacák, K. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.017 · Cited by 116
Benn, D. E., Croxson, M. S., Tucker, K., Bambach, C. P., Richardson, A. L., Delbridge, L., Pullan, P. T., Hammond, J., Marsh, D. J., & Robinson, B. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206300 · Cited by 108
“Subsequent to our submission of this manuscript the SDHB mutation R46Q was reported in the germline of a patient with an apparently sporadic malignant phaeochromocytoma (Gimenez-Roqueplo et al., 2002).”
BackgroundMultigene methylation analysis of Wilms' tumour and adult renal cell carcinoma
Morris, M. R., Hesson, L. B., Wagner, K. J., Morgan, N. V., Astuti, D., Lees, R. D., Cooper, W. N., Lee, J., Gentle, D., MacDonald, F., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206914 · Cited by 112
“SDHB inactivation in phaeochromocytoma has been suggested to result in the activation of hypoxic response pathways (Gimenez-Roqueplo et al., 2002), but we did not find any evidence that SDHB inactivation in clear cell RCC represents a frequent mechanism for a non-VHL pathway for HIF dysregulation…”
BackgroundSIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells
Khan, R. S., Fonseca-Kelly, Z., Callinan, C., Zuo, L., Sachdeva, M. M., & Shindler, K. S. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00063 · Cited by 105
On the association of succinate dehydrogenase mutations with hereditary paraganglioma
Baysal, B. E. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.08.004 · Cited by 106
SDH-related pheochromocytoma and paraganglioma
Kantorovich, V., King, K. S., & Pacák, K. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.04.001 · Cited by 113
New targets and therapeutic approaches for endocrine malignancies☆
Fassnacht, M., Kreissl, M. C., Weismann, D., & Allolio, B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.013 · Cited by 107
Cells Silenced for SDHB Expression Display Characteristic Features of the Tumor Phenotype
Cervera, A. M., Apostolova, N., Crespo, F. L., Mata, M., & McCreath, K. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5580 · Cited by 98
“In comparison, SDH activity caused by either SDHB or SDHD mutations in clinical tumor samples, is undetectable (7, 8).”
Lemarie, A., Huc, L., Pazarentzos, E., Mahul-Mellier, A.-L., & Grimm, S. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.93 · Cited by 98
“These findings are also supported by other independent studies showing that, in cancer patients with mutations in complex II subunits, the remaining components of this complex are either not present(40) or display a profoundly reduced complex II activity.(41) Hence, in tumours harbouring such altered genes, the combin…”
Pheochromocytomas and secreting paragangliomas
Plouin, P., & Gimenez‐Roqueplo, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-49 · Cited by 106
“In hereditary cases with germline SDHD or SDHB mutations, the tumors exhibit loss of the remaining wild-type allele with complete inhibition of complex II electron transfer activity, leading to activation of pro-angiogenic hypoxic-inducible transcription factors (HIFs) [9-11].”
BackgroundSelf-citationDouwes Dekker, P., Hogendoorn, P., Kuipers‐Dijkshoorn, N., Prins, F., van Duinen, S., Taschner, P., van der Mey, A., & Cornelisse, C. (2003) · The Journal of Pathology · doi:10.1002/path.1461 · Cited by 94
“SDHB mutations also impair SDH activity, presumably through inactivation of iron-protein function [15,28].”
BackgroundHereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency
Favier, J., Brière, J.-J., Strompf, L., Amar, L., Filali, M., Jeunemaitre, X., Rustin, P., & Gimenez-Roqueplo, A.-P. (2005) · Hormone Research in Paediatrics · doi:10.1159/000084685 · Cited by 88
Self-citationNuclear genes in mitochondrial disorders
Zeviani, M., Spinazzola, A., & Carelli, V. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00052-2 · Cited by 98
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 83
“In support of this mechanism as a link between complex II mutations and cancer, increased cytoplasmic succinate levels have been confirmed in SDH–A [21], –B [22], –C and –D [11,23] mutants in association with an activated HIF pathway (see also[24,25]).”
BackgroundParagangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing
Martins, R., & Bugalho, M. J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/794187 · Cited by 90
Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma
Hensen, E. F., & Bayley, J. (2010) · Familial Cancer · doi:10.1007/s10689-010-9402-1 · Cited by 90
“In contrast, SDH-related tumors, including SDHD [12], SDHB [40], SDHA [9] and SDHAF2 [12] carry an inactivating mutation which, combined with the loss of the wild type allele (LOH), results in almost complete loss of activity.”
BackgroundClinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
Eijkelenkamp, K., Osinga, T. E., Links, T. P., & van der Horst‐Schrivers, A. N. A. (2019) · Clinical Genetics · doi:10.1111/cge.13553 · Cited by 103
Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate
Goncalves, J., Moog, S., Morin, A., Gentric, G., Müller, S., Morrell, A. P., Kľučková, K., Stewart, T. J., Andoniadou, C. L., Lussey‐Lepoutre, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2936 · Cited by 81
“1C), and in accordance with observations in mutated human PPGL (9, 26).”
ResultSelf-citationPheochromocytoma and Paraganglioma
Kantorovich, V., & Pacák, K. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82015-1 · Cited by 95
van Berkel, A., Rao, J. U., Küsters, B., Demir, T., Visser, E. P., Mensenkamp, A. R., van der Laak, J. A. W. M., Oosterwijk, E., Lenders, J. W. M., Sweep, F. C. G. J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.137034 · Cited by 80
Kouba, E., & Liang Cheng, C. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9444-5 · Cited by 75
Timmers, H. J. L. M., Taïeb, D., & Pacák, K. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1299712 · Cited by 79
Pheochromocytoma and Paraganglioma
Pacák, K., & Wimalawansa, S. J. (2015) · Endocrine Practice · doi:10.4158/ep14481.ra · Cited by 77
Evolving concepts in pheochromocytoma and paraganglioma
Dahia, P. L. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198017.45982.06 · Cited by 69
The basic science of glomus jugulare tumors
Heth, J. (2004) · Neurosurgical FOCUS · doi:10.3171/foc.2004.17.2.2 · Cited by 70
Blank, A., Schmitt, A. M., Korpershoek, E., van Nederveen, F., Rudolph, T., Weber, N., Strebel, R. T., de Krijger, R., Komminoth, P., & Perren, A. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0316 · Cited by 67
Pheochromocytoma: The First Metabolic Endocrine Cancer
Jochmanová, I., & Pacák, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0606 · Cited by 70
“significantly more expressed in SDHx-mutated tumors compared with sporadic ones (68, 69).”
BackgroundSuccinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome
Settas, N., Faucz, F. R., & Stratakis, C. A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.018 · Cited by 70
Rao, J. U., Engelke, U. F. H., Rodenburg, R. J., Wevers, R. A., Pacák, K., Eisenhofer, G., Qin, N., Küsters, B., Goudswaard, A. G., Lenders, J. W. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3922 · Cited by 67
RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA
Gimenez‐Roqueplo, A., Burnichon, N., Amar, L., Favier, J., Jeunemaître, X., & Plouin, P. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04881.x · Cited by 66
“We have demonstrated that SDH inactivation leads to the selective and complete inhibition of this enzymatic activity.(8,19,20) Succinate accumulates in SDH-related PH, causing an imbalance in succinate/ oxaloglutarate levels.”
BackgroundResultSelf-citationMutations of the SDHB and SDHD genes
Pawlu, C., Bausch, B., & Neumann, H. P. H. (2005) · Familial Cancer · doi:10.1007/s10689-004-4227-4 · Cited by 65
“Accordingly, expression of hypoxic-angiogenic responsive genes was shown for SDHB and SDHD mutations [4, 5].”
BackgroundModel animals for the study of oxidative stress from complex II
Ishii, T., Miyazawa, M., Onouchi, H., Yasuda, K., Hartman, P. S., & Ishii, N. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.016 · Cited by 65
“Arg46Gln) in a malignant PHEO with somatic terminal deletion of 1p [57,58].”
BackgroundResultMetastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options
Nölting, S., Grossman, A. B., & Pacák, K. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1888 · Cited by 66
“For example, overexpression of HIF-2α has been described in patients with PCCs and PGLs with SDHB and SDHD mutations [29, 30].”
Selak, M. A., Durán, R. V., & Gottlieb, E. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.05.015 · Cited by 59
Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency
Pitsava, G., Settas, N., Faucz, F. R., & Stratakis, C. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680609 · Cited by 61
Penetrance and clinical consequences of a gross SDHB deletion in a large family
Solis, D. C., Burnichon, N., Timmers, H., Raygada, M. J., Kozupa, A., Merino, M. J., Makey, D., Adams, K. T., Vénisse, A., Gimenez‐Roqueplo, A., et al. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01157.x · Cited by 57
“Loss of heterozygosity (LOH) studies were performed as previously described (8).”
MethodSelf-citationSuccinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics
Her, Y. F., & Maher, L. J. (2015) · International Journal of Endocrinology · doi:10.1155/2015/296167 · Cited by 58
“The PGL syndrome associated with SDHB gene mutations was identified by Astuti and colleagues [74]; see [75, 76].”
BackgroundAntiangiogenic therapies for pheochromocytoma and paraganglioma
Jiménez, C., Fazeli, S., & Román-Gonzaléz, A. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0043 · Cited by 59
Zeviani, M., & Carelli, V. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200310000-00004 · Cited by 53
Functional Diagnostics in Mitochondrial Diseases
Siciliano, G., Volpi, L., Piazza, S., Ricci, G., Mancuso, M., & Murri, L. (2007) · Bioscience Reports · doi:10.1007/s10540-007-9037-0 · Cited by 51
“Inactivation of the SDH gene is also associated with stimulation of the angiogenic pathway (Gimenez-Roqueplo et al. 2002).”
BackgroundSun, G., Zhao, S., Fan, Z., Wang, Y., Liu, H., Cao, H., Sun, G., Huang, T., Cai, H., Pan, H., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02803-0 · Cited by 51
“Increased succinate and expression of HIF1α and angiogenic genes, such as VEGF, as well as high density of microvessels were found in pheochromocytoma tumor tissues [45].”
BackgroundCastelblanco, E., Santacana, M., Valls, J., Cubas, A. D., Cascón, A., Robledo, M., & Matías‐Guiu, X. (2013) · Endocrine Pathology · doi:10.1007/s12022-013-9269-4 · Cited by 51
“They can occur at a very young age [13, 32].”
BackgroundInfluentialExtracellular Succinate: A Physiological Messenger and a Pathological Trigger
Wu, K. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311165 · Cited by 52
Dahia, P. L. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.023 · Cited by 56
Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma
Astuti, D., Morris, M. R., Krona, C. C., Abel, F., Gentle, D., Martinsson, T., Kogner, P., Neumann, H. P. H., Voutilainen, R., Eng, C., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602202 · Cited by 52
“SDHB inactivation may lead to upregulation of a wide range of hypoxia-inducible genes (Gimenez-Roqueplo et al, 2002).”
BackgroundMethodSelf-citationLemarié, A., & Grimm, S. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.03.004 · Cited by 53
“Of note, there are some indications that complex II subunit mutations found in human tumours could also lead to complex II destabilisation (Douwes Dekker et al., 2003) or display a profoundly reduced complex II activity (Gimenez-Roqueplo et al., 2001, 2002).”
BackgroundTsang, V., Dwight, T., Benn, D. E., Meyer-Rochow, G. Y., Gill, A. J., Sywak, M. S., Sidhu, S., Veivers, D., Sue, C. M., Robinson, B. G., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0519 · Cited by 48
Zantour, B., Guilhaume, B., Tissier, F., Louvel, A., Jeunemaître, X., Gimenez‐Roqueplo, A., & BERTAGNA, X. Y. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510433 · Cited by 49
Self-citationSuccinate dehydrogenase subunit B inhibits the AMPK-HIF-1¿ pathway in human ovarian cancer in vitro
Chen, L., Liu, T., Zhang, S., Zhou, J., Wang, Y., & Di, W. J. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0115-1 · Cited by 56
“Immunohistochemical analysis shows strong staining of hypoxiainducible factor-1α (HIF-1α) and the angiogenic factor, vascular endothelial growth factor in a malignant sporadic pheochromocytoma caused by a germline missense mutation in the SDHB gene [13], suggesting that activation of the hypoxia-response pathway may b…”
BackgroundSuccinate at the Crossroad of Metabolism and Angiogenesis: Roles of SDH, HIF1α and SUCNR1
Atallah, R., Olschewski, A., & Heinemann, Á. (2022) · Biomedicines · doi:10.3390/biomedicines10123089 · Cited by 47
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 45
“To support this hypothesis, mutations in SDH subunits D and B in tumors from families with paragangliomas were found to activate the HIF1α pathway and be highly vascularized [118,119].”
BackgroundSpan, P. N., Rao, J. U., Ophuis, S. B. J. O., Lenders, J. W. M., Sweep, F. C. G. J., Wesseling, P., Küsters, B., van Nederveen, F. H., de Krijger, R. R., Hermus, A. R. M. M., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0184 · Cited by 47
Aghamir, S. M. K., Heshmat, R., Ebrahimi, M., Ketabchi, S. E., Parichehreh-Dizaji, S., & Khatami, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s207460 · Cited by 41
“SDHB is the Fe–S subunit of mitochondrial complex II including extremely consensus L (I)YR motifs essential for gaining of Fe–S clusters by recruiting the Fe–S transfer machinery.(65,66) Importantly, the c.”
BackgroundStructural and functional consequences of succinate dehydrogenase subunit B mutations
Kim, E., Rath, E. M., Tsang, V., Duff, A. P., Robinson, B. G., Church, W. B., Benn, D. E., Dwight, T., & Clifton-Bligh, R. J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0099 · Cited by 39
“Many studies (Gimenez-Roqueplo et al. 2001, 2002, Lima et al. 2007) have emphasised the importance of SDH structural integrity, and that specific mutations in any of the SDH subunits would disrupt assembly, anchorage to the mitochondrial membrane, surface exposure of binding sites and stabilisation…”
BackgroundMitochondrial superoxide anion (O2·-) inducible "mev-1" animal models for aging research
Ishii, T., Miyazawa, M., Hartman, P. S., & Ishii, N. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.5.298 · Cited by 39
“A mutation in SDHB, SDHC or SDHD was found in patients of PGL/PHEO syndromes (51-55).”
BackgroundPuar, T., van Berkel, A., Gotthardt, M., Havekes, B., Hermus, A. R. M. M., Lenders, J. W. M., van Marken Lichtenbelt, W. D., Xu, Y., Brans, B., & Timmers, H. J. L. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3205 · Cited by 37
Metadata
- Authors
- Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Kerlan, V., Plouin, P.-F., Rötig, A., & Jeunemaitre, X.
- Affiliations
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10
- Volume
- 87
- Issue
- 10
- Pages
- 4771-4774
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2144878030
- Cited by
- 209
- References
- 13
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 6 · 2015: 14 · 2014: 15 · 2013: 13 · 2012: 15
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- sporadic pheochromocytoma, succinate dehydrogenase, loss of heterozygosity, hypoxia-inducible factor, angiogenesis, oxygen sensing, neural crest-derived tumors, hereditary paraganglioma, germline missense mutation, tumor suppressor
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adrenal Gland Neoplasms, Chromosomes, Human, Pair 1, DNA Mutational Analysis, Female, Humans, Immunohistochemistry, Iron-Sulfur Proteins, Lymphokines, Middle Aged, Multienzyme Complexes, Mutation, Oxidoreductases, Pheochromocytoma, RNA, Messenger, Succinate Dehydrogenase, Tomography, X-Ray Computed, Trans-Activators, Gene Expression, Endothelial Growth Factors, In Situ Hybridization, Sequence Analysis, DNA, Germ-Line Mutation, Loss of Heterozygosity, Mutation, Missense, Protein Subunits, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Electron Transport Complex II, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.